Insulin resistance is associated with incident chronic kidney disease in population with normal renal function

Article information

Korean J Nephrol. 2023;.j.krcp.22.298
Publication date (electronic) : 2023 December 13
doi : https://doi.org/10.23876/j.krcp.22.298
Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea
Correspondence to: Eun Hui Bae Department of Internal Medicine, Chonnam National University Medical School, 42 Jebong-ro, Gwangju 61469, Republic of Korea. E-mail: baedak76@gmail.com
Received 2022 December 23; Revised 2023 May 30; Accepted 2023 June 20.

Abstract

Background

Insulin resistance is prevalent in chronic kidney disease, and may accelerate the progression of chronic kidney disease. This study aimed to investigate whether insulin resistance is associated with the development of incident chronic kidney disease in a population with normal renal function.

Methods

A total of 3,331 participants from a community-based cohort with normal renal function were prospectively analyzed. We determined the relationship of insulin resistance indices with the incident chronic kidney disease using the Cox proportional hazard model and Kaplan-Meier survival analysis.

Results

During a mean follow-up of 11.03 ± 4.22 years, incident chronic kidney disease occurred in 414 participants (12.4%). The high homeostasis model assessment-insulin resistance level group had an increased risk of incident chronic kidney disease (hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.13–1.74; p = 0.002) compared to the normal group after adjustment for age, sex, history of hypertension, body mass index, total cholesterol, alcohol drinking status, smoking status, and baseline estimated glomerular filtration rate. The risk of incident chronic kidney disease also increased with the lower quantitative insulin sensitivity check index level (HR, 0.62; 95% CI, 0.41–0.92; p = 0.02) and higher leptin-adiponectin ratio level (HR, 1.23; 95% CI, 1.06–1.42; p = 0.006).

Conclusion

Higher insulin resistance indices are associated with the incidence of chronic kidney disease. Our data suggest that increased insulin resistance may be involved in the development of incident chronic kidney disease in a population with normal renal function.

Introduction

Insulin resistance is defined as reduced sensitivity of target organs to the effects of insulin, leading to a compensatory rise in circulating insulin to maintain normal blood glucose levels [13]. Insulin resistance contributes to obesity, type 2 diabetes mellitus (DM), hypertension (HTN), and metabolic syndrome [46]. Insulin resistance is prevalent in both diabetic and nondiabetic patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) [79]. Insulin resistance itself may also accelerate the progression of CKD. For instance, one study reported that insulin resistance was directly related to low glomerular filtration rate (GFR) [10], and another study reported that insulin resistance was associated with the progression of immunoglobulin A nephropathy [11]. However, the precise mechanisms by which insulin resistance affects renal dysfunction in CKD remain poorly identified. Further, the association between insulin resistance and renal dysfunction in a population with normal renal function is not unclear.

For assessment of insulin resistance, the hyperinsulinemic euglycemic glucose clamp is the gold standard because it directly measures the effects of insulin to promote glucose utilization under steady state [12]. However, the complexity of the methodology and labor-intensive procedure limits its use. Therefore, a simple index for insulin resistance, such as homeostasis model assessment-insulin resistance (HOMA-IR), is widely used in clinical studies [13]. There are also several other indices including the quantitative insulin sensitivity check index (QUICKI), homeostasis model assessment-adiponectin (HOMA-AD), and leptin-adiponectin ratio (LAR) [4,14].

In this study, we aimed to investigate whether insulin resistance is associated with the development of incident CKD in the general population from the Korean Genome and Epidemiology Study (KoGES), which is a community-based prospective cohort study [15]. We also evaluated the difference in the effects of insulin resistance indices on the development of incident CKD.

Methods

This study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Chonnam National University Hospital (No. CNUH-EXP-2022-140). All the study participants voluntarily enrolled in this study after providing informed consent.

Study population

The KoGES is a large prospective community-based cohort study funded by the government. The detailed profile and methods concerning the development of KoGES have been previously described [15]. In this study, participants who were residents of Ansan, which is a city in the Republic of Korea, were recruited from the KoGES cohort population. A total of 5,012 participants (age range, 40–69 years) were recruited. Serial health examinations and surveys were performed biennially from 2001 to 2018. From the study database, we excluded those with estimated GFR (eGFR) of <60 mL/min/1.73 m2. We also excluded those with missing baseline serum creatinine and missing baseline serum fasting glucose or fasting insulin. A total of 3,331 participants were included in the final analysis (Fig. 1).

Figure 1.

Flow diagram of the study population.

eGFR, estimated glomerular filtration rate of KoGES, Korean Genome and Epidemiology Study;

Anthropometric and laboratory data

All participants underwent comprehensive medical health examinations and filled out questionnaires on health and lifestyle at the time of enrollment. Demographic and socioeconomic data, including age, sex, alcohol intake, smoking status, and medical histories were obtained. HTN was diagnosed on the basis of the responses to the past medical history in the administered questionnaire. Anthropometric parameters such as height and body weight were measured by skilled study workers following standard methods. Blood and urine samples were obtained after an 8-hour fasting and transported to a central laboratory (Seoul Clinical Laboratories, Seoul, Republic of Korea). The following biochemical data were determined using fasting blood samples: concentrations of blood urea nitrogen, creatinine, albumin, glucose, total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, hemoglobin A1c, hemoglobin, and C-reactive protein. Serum creatinine levels were measured using an isotope dilution mass spectrometry-traceable method. The eGFR was calculated by using CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation [16].

Total serum adiponectin and leptin concentrations were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Mercodia). Insulin was measured in the fasting serum samples using an immunoradiometric assay (Gammar Counter_Cobra; Packard).

Insulin indices, study outcomes, and definitions

Insulin resistance was determined by the HOMA-IR: fasting glucose (mg/dL) × fasting insulin (µIU/mL)/405 [13]. The other insulin resistance indices were also calculated: QUICKI, 1 / (log fasting glucose [mg/dL] + log fasting insulin [µIU/mL]); HOMA-AD, fasting glucose (mg/dL) × fasting insulin (µIU/mL) / (405 × adiponectin [mg/mL]); and LAR, leptin (mg/mL) / adiponectin (mg/mL). The higher the HOMA-IR, HOMA-AD, and LAR levels, the higher the insulin resistance. On the other hand, the lower the QUICKI level, the higher the insulin resistance [4].

The endpoint was incident CKD, which was defined as a composite eGFR of <60 mL/min/1.73 m2 during the follow-up period. In our study, we defined the ‘high group’ as individuals with a HOMA-IR level greater than the 75th percentile value for participants, and the level was >1.9.

Statistical analysis

Statistical analyses were performed using R version 4.0.2 (R Foundation for Statistical Computing). Continuous variables are expressed as mean ± standard deviation, and categorical variables as number (percentage). All data were tested for normality before the statistical analysis. A t test or Mann-Whitney U test was conducted to compare continuous variables. Meanwhile, the chi-square test was performed to compare categorical variables. We used a restricted cubic spline curve to illustrate the nonlinear association between the HOMA-IR level and the risk of incident CKD. We used four knots for the restricted cubic spline curve. The Kaplan-Meier survival curves with log-rank tests and a univariate Cox proportional hazards model were used to examine the effect of HOMA-IR level on incident CKD. Multivariate Cox proportional hazards regression analysis was used to assess independent variables with incident CKD. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to estimate the risk of incident CKD. We examined the as sumption of the proportional hazard in the Cox model using cox.zph() in R. Age and sex-adjusted HRs were first calculated (model 1), and the results were further adjusted for HTN, body mass index (BMI), and total cholesterol (model 2). The results were further adjusted for alcohol drinking, smoking status, and baseline eGFR (model 3). For all analyses, a p-value of <0.05 was considered statistically significant.

Results

Baseline characteristics of the study population

The participants’ baseline characteristics according to their HOMA-IR level are presented in Table 1. We defined the ‘high group’ as individuals with a HOMA-IR level of >1.9. Participants in the high group were predominantly male (54.0% vs. 48.7%, p = 0.008), had a higher incidence of HTN (17.6% vs. 9.5%, p < 0.001), had a higher serum creatinine (0.9 mg/dL vs. 0.8 mg/dL, p < 0.001), had a higher hemoglobin (13.9 g/dL vs. 13.6 g/dL, p < 0.001), had a higher total cholesterol (202.1 mg/dL vs. 193.9 mg/dL, p < 0.001), and had a higher BMI (26.0 kg/m2 vs. 24.2 kg/m2, p < 0.001) than those in the normal group.

Baseline characteristics of the study population

Risk of incident chronic kidney disease by homeostasis model assessment-insulin resistance

During a mean follow-up of 11.03 ± 4.22 years, incident CKD occurred in 414 participants (12.4%). We created a Cox regression model using a restricted cubic spline curve to assess the association between HOMA-IR level and HR of incident CKD (Fig. 2). The HOMA-IR level exhibited a positive correlation with incident CKD risk.

Figure 2.

Restricted cubic spline curve of hazard ratio of HOMA-IR level for incident chronic kidney disease probability.

The HOMA-IR level exhibited a positive correlation with incident chronic kidney disease risk.

HOMA-IR, homeostasis model assessment-insulin resistance.

Multivariable Cox proportional hazard models were used to determine whether HOMA-IR level and falling into the high HOMA-IR group were independent risk factors for incident CKD (Table 2). After adjustment for age, sex, history of HTN, BMI, total cholesterol, alcohol drinking status, smoking status, and baseline eGFR, the risk of incident CKD increased with higher HOMA-IR levels (HR, 1.13; 95% CI, 1.05–1.22; p = 0.001). Compared with the normal group, the high group had an increased risk of incident CKD (HR, 1.40; 95% CI, 1.13–1.74; p = 0.002).

HR for incident chronic kidney disease by HOMA-IR with Cox proportion hazard models

The Kaplan-Meier curves for free-CKD probability according to the normal and high groups are shown in Fig. 3. The high group showed a significantly higher risk for the development of CKD compared to the normal group (p < 0.001).

Figure 3.

The Kaplan-Meier free-CKD probability curve with the log-rank test between high HOMA-IR group and incident CKD.

High group is associated with poor free-CKD probability.

CKD, chronic kidney disease; HOMA-IR, homeostasis model assessment-insulin resistance.

Impact of insulin resistance indices on incident chronic kidney disease

Next, we evaluated the association between other insulin resistance indices and the risk of incident CKD. Multivariable Cox proportional hazard models were used to determine whether insulin resistance indices were independent risk factors for incident CKD (Table 3). After adjustment for age, sex, history of HTN, BMI, total cholesterol, alcohol drinking status, smoking status, and baseline eGFR, the risk of incident CKD increased with the lower QUICKI levels (HR, 0.62; 95% CI, 0.41–0.92; p = 0.02) and higher LAR level (HR, 1.23; 95% CI, 1.06–1.42; p = 0.006).

HR for incident chronic kidney disease by HOMA-IR, QUICKI, HOMA-AD, LAR, and HbA1C with Cox proportion hazard models

Subgroup analyses

To evaluate whether the association of HOMA-IR level and the risk of incident CKD is modified by subgroups, we conducted subgroup analyses (Fig. 4). The subgroups were stratified by age (<60 or ≥60 years), sex, HTN, and obesity (BMI ≥25 kg/m2 or <25 kg/m2). Cox regression analysis regarding the association between HOMA-IR level and the risk of incident CKD revealed that p for interaction was >0.05 for all subgroups, suggesting that the association of high HOMA-IR level with increased risk of incident CKD is not modified by these factors.

Figure 4.

Cox regression analysis of HOMA-IR for incident chronic kidney disease in various subgroups.

Models were adjusted for age, sex, hypertension (HTN), body mass index, total cholesterol, alcohol drinking, smoking, and estimated glomerular filtration rate (eGFR).

CI, confidence interval; HR, hazard ratio; HOMA-IR, homeostasis model assessment-insulin resistance.

Discussion

In this study, we identified a significant positive association between increased insulin resistance and incident CKD in a population with normal renal function. Higher HOMA-IR levels significantly increased the risk of incident CKD in multivariable analyses. Moreover, higher LAR levels and lower QUICKI levels also increased the risk of incident CKD. These findings suggest that management of insulin resistance is helpful in preserving renal function even in a population with normal renal function. In addition, our subgroup analyses showed that insulin resistance had an effect on incident CKD regardless of age, sex, and HTN. This result reinforces that management of insulin resistance is important in the general population.

Our findings are consistent with those of the previous community-based studies that investigated the cross-sectional association of insulin resistance and GFR [10,17]. These studies assessed the insulin resistance by HOMA-IR or hyperinsulinemic euglycemic glucose clamp, and increased insulin resistance was found to be associated with low GFR. However, these studies had limitations of being cross-sectional studies. Our study is noteworthy because of long-term follow-up performing survival analysis.

Insulin resistance has been suggested to contribute to the development of renal impairment via numerous different pathophysiologic pathways. Hyperglycemia and hyperinsulinemia promote the expression and activation of insulin-like growth factor (IGF)-1, transforming growth factor beta (TGF-β), and endothelin-1 whose profibrotic activity leads to increased production of extracellular matrix by mesangial cells [18,19]. Insulin and IGF-1 molecules are similar; thus insulin can act on the IFG-1 receptors and promote vascular proliferation through both enhancing IGF-1 production and stimulating its receptors [20]. Insulin also stimulates TGF-β1 production from the proximal tubule cells, leading to an increase in type IV collagen gene expression and its accumulation in the extracellular matrix [21].

Insulin resistance and hyperinsulinemia are also associated with oxidative stress. Oxidative stress is defined as a disturbance in the normal homeostatic balance between reactive oxygen species and antioxidant substances [22]. Glucose control plays an important role in the homeostatic balance, and hyperglycemia is well known to cause oxidative stress through various mechanisms: glucose autoxidation, protein glycation and formation of advanced glycation end products, and the polyol pathway [23]. Oxidative stress plays an important role in tubulointerstitial fibrosis and glomerulosclerosis by myofibroblast activation, mesangial sclerosis, and parietal epithelial cell injury [24]. Increased oxidative stress has been reported in patients with stage 3 to 5 CKD, especially in patients with DM and hypercholesterolemia [25].

Insulin resistance is associated with increased activity of proinflammatory cytokines that contribute to increased risk of endothelial dysfunction and atherosclerosis [1]. Endothelial dysfunction and arterial stiffness are pervasive in CKD and ESRD and are themselves risk factors for renal deterioration. Endothelial dysfunction exacerbates renal interstitial fibrosis through increased fibroblast proliferation and collagen production [26]. Endothelial dysfunction and atherosclerosis are powerful predictors of cardiovascular mortality in a population with CKD. Several studies suggest that insulin resistance is associated with the risk of cardiovascular disease in patients with CKD by contributing to the pathogenesis of atherosclerosis, endothelial dysfunction, and chronic inflammation [1,2729]. In a prior study, HOMA-IR predicted cardiovascular mortality in patients with ESRD [29].

HOMA-IR has been reported to contribute to the progression of renal dysfunction in patients with CKD [30,31]. However, our study has certain strengths and originalities including a large sample size, prospective study design, community-based study, and long-term follow-up performing survival analysis. Moreover, not only HOMA-IR but also other insulin resistance indices were used to estimate insulin resistance. This study has some limitations. HOMA-IR is calculated from a single measurement of serum glucose and insulin; hence, it cannot reflect the changes in beta cell dysfunction over time. Further, although the gold standard method to measure insulin resistance and changes in beta cell dysfunction is the hyperinsulinemic euglycemic glucose clamp, we did not use the method. However, in the real practice world, it is a complex and labor-intensive procedure to use. We suggest the usefulness of insulin resistance indices such as HOMA-IR by identifying the association between insulin resistance indices and incident CKD.

In conclusion, increased insulin resistance was associated with incident CKD in a population with normal renal function. Efforts to reduce insulin resistance, such as weight loss and diet control, can lead to the protection of renal function in a healthy population.

Notes

Conflicts of interest

All authors have no conflicts of interest to declare.

Funding

This research was supported by a grant from Chonnam National University Hospital Biomedical Research Institute (No. BCRI22040) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2019R1A2C1003971&RS-2023-00217317).

Data sharing statement

The data presented in this study were from the Korean Genome and Epidemiology Study (KoGES; 6635-302), National Institute of Health, Korea Disease Control and Prevention Agency, Republic of Korea.

Authors’ contributions

Conceptualization: SH Song, YJG, TRO, SH Suh, HSC, CSK, EHB

Formal analysis: SH Song, YJG, TRO, EHB

Funding acquisition: EHB

Writing–original draft, Writing–review & editing: SH Song, EHB

All authors read and approved the final manuscript.

References

1. Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol 2016;311:F1087–F1108.
2. Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 1991;325:938–948.
3. Schrauben SJ, Jepson C, Hsu JY, et al. Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study. BMC Nephrol 2019;20:60.
4. Masquio DC, Ganen Ade P, Campos RM, et al. Cut-off values of waist circumference to predict metabolic syndrome in obese adolescents. Nutr Hosp 2015;31:1540–1550.
5. Bloomgarden ZT. Obesity, hypertension, and insulin resistance. Diabetes Care 2002;25:2088–2097.
6. Jonk AM, Houben AJ, de Jongh RT, Serné EH, Schaper NC, Stehouwer CD. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology (Bethesda) 2007;22:252–260.
7. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005;45:275–280.
8. Barazzoni R, Zanetti M, Stulle M, et al. Higher total ghrelin levels are associated with higher insulin-mediated glucose disposal in non-diabetic maintenance hemodialysis patients. Clin Nutr 2008;27:142–149.
9. de Boer IH, Zelnick L, Afkarian M, et al. Impaired glucose and insulin homeostasis in moderate-severe CKD. J Am Soc Nephrol 2016;27:2861–2871.
10. Nerpin E, Risérus U, Ingelsson E, et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care 2008;31:1550–1555.
11. Kaartinen K, Syrjänen J, Pörsti I, et al. Insulin resistance and the progression of IgA glomerulonephritis. Nephrol Dial Transplant 2007;22:778–783.
12. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214–E223.
13. Hung AM, Sundell MB, Egbert P, et al. A comparison of novel and commonly-used indices of insulin sensitivity in African American chronic hemodialysis patients. Clin J Am Soc Nephrol 2011;6:767–774.
14. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 2005;54:1914–1925.
15. Kim Y, Han BG, ; KoGES group. Cohort profile: the Korean Genome and Epidemiology Study (KoGES) Consortium. Int J Epidemiol 2017;46e20.
16. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612.
17. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003;14:469–477.
18. Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 2006;26:232–244.
19. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008;4:444–452.
20. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143–163.
21. Morrisey K, Evans RA, Wakefield L, Phillips AO. Translational regulation of renal proximal tubular epithelial cell transforming growth factor-beta1 generation by insulin. Am J Pathol 2001;159:1905–1915.
22. Betteridge DJ. What is oxidative stress? Metabolism 2000;49(2 Suppl 1):3–8.
23. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000;26:163–176.
24. Su H, Wan C, Song A, Qiu Y, Xiong W, Zhang C. Oxidative stress and renal fibrosis: mechanisms and therapies. Adv Exp Med Biol 2019;1165:585–604.
25. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65:1009–1016.
26. Sun YB, Qu X, Li X, Nikolic-Paterson DJ, Li J. Endothelial dysfunction exacerbates renal interstitial fibrosis through enhancing fibroblast Smad3 linker phosphorylation in the mouse obstructed kidney. PLoS One 2013;8e84063.
27. Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005;1:100–110.
28. De Cosmo S, Menzaghi C, Prudente S, Trischitta V. Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence. Nephrol Dial Transplant 2013;28:29–36.
29. Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002;13:1894–1900.
30. Caravaca F, Cerezo I, Macías R, et al. [Insulin resistance in chronic kidney disease: its clinical characteristics and prognosis significance]. Nefrologia 2010;30:661–668. In Spanish.
31. Kobayashi H, Tokudome G, Hara Y, et al. Insulin resistance is a risk factor for the progression of chronic kidney disease. Clin Nephrol 2009;71:643–651.

Article information Continued

Figure 1.

Flow diagram of the study population.

eGFR, estimated glomerular filtration rate of KoGES, Korean Genome and Epidemiology Study;

Figure 2.

Restricted cubic spline curve of hazard ratio of HOMA-IR level for incident chronic kidney disease probability.

The HOMA-IR level exhibited a positive correlation with incident chronic kidney disease risk.

HOMA-IR, homeostasis model assessment-insulin resistance.

Figure 3.

The Kaplan-Meier free-CKD probability curve with the log-rank test between high HOMA-IR group and incident CKD.

High group is associated with poor free-CKD probability.

CKD, chronic kidney disease; HOMA-IR, homeostasis model assessment-insulin resistance.

Figure 4.

Cox regression analysis of HOMA-IR for incident chronic kidney disease in various subgroups.

Models were adjusted for age, sex, hypertension (HTN), body mass index, total cholesterol, alcohol drinking, smoking, and estimated glomerular filtration rate (eGFR).

CI, confidence interval; HR, hazard ratio; HOMA-IR, homeostasis model assessment-insulin resistance.

Table 1.

Baseline characteristics of the study population

Characteristic Total population (n = 3,331)
p-value
Normal group High groupa
No. of patients 2,421 910
Age (yr) 48.8 ± 7.6 49.0 ± 7.8 0.48
Male sex 1,179 (48.7) 491 (54.0) 0.008
Education 0.26
 No education or elementary school graduate 376 (15.6) 155 (17.1)
 Middle school graduate 542 (22.4) 177 (19.5)
 High school graduate 1,028 (42.5) 380 (41.9)
 More than college graduate 471 (19.5) 195 (21.6)
Alcohol drinking status 0.12
 Never 1,084 (44.9) 374 (41.2)
 Ex-drinker 121 (5.0) 55 (6.1)
 Drinker 1,211 (50.1) 479 (52.8)
Smoking status 0.045
 Never 1,431 (59.5) 495 (54.5)
 Ex-smoker 423 (17.6) 180 (19.8)
 Current smoker 553 (23.0) 233 (25.7)
Hypertension 229 (9.5) 160 (17.6) <0.001
Systolic BP (mmHg) 114.9 ± 17.3 119.6 ± 17.1 <0.001
Diastolic BP (mmHg) 77.8 ± 11.8 81.0 ± 11.6 <0.001
BUN (mg/dL) 13.6 ± 3.5 14.0 ± 3.5 0.003
Creatinine (mg/dL) 0.8 ± 0.2 0.9 ± 0.2 <0.001
eGFR (mL/min/1.73 m2) 94.3 ± 14.8 92.3 ± 15.3 0.001
UPCR (g/gCr) 0.1 ± 0.3 0.1 ± 0.2 0.99
Hemoglobin (g/dL) 13.6 ± 1.6 13.9 ± 1.5 <0.001
Serum albumin (g/dL) 4.6 ± 0.3 4.6 ± 0.3 0.27
Na (mmol/L) 142.8 ± 2.2 142.8 ± 2.2 0.78
K (mmol/L) 4.5 ± 0.5 4.4 ± 0.4 <0.001
Total cholesterol (mg/dL) 193.9 ± 34.6 202.1 ± 38.2 <0.001
HDL cholesterol (mg/dL) 45.5 ± 10.1 42.7 ± 9.1 <0.001
LDL cholesterol (mg/dL) 118.5 ± 32.5 121.0 ± 35.0 0.07
Triglyceride (mg/dL) 149.0 ± 96.8 192.0 ± 127.2 <0.001
Body mass index (kg/m2) 24.2 ± 2.8 26.0 ± 3.0 <0.001
HOMA-IR 1.2 ± 0.4 2.7 ± 1.2 <0.001
QUICKI 3.7 ± 0.2 3.3 ± 0.1 <0.001
HOMA-AD 3.9 ± 2.4 5.4 ± 2.7 <0.001
LAR 1.7 ± 1.8 2.3 ± 1.9 <0.001

Data are expresses as number only, mean ± standard deviation, or number (%).

BUN, blood urea nitrogen; BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HOMA-AD, homeostasis model assessment-adiponectin; HOMA-IR, homeostasis model assessment-insulin resistance; K, potassium; LAR, leptin-adiponectin ratio; LDL, low-density lipoprotein; Na, sodium; QUICKI, quantitative insulin sensitivity check index; UPCR, urine protein-creatinine ratio.

a

High group is defined as HOMA-IR > 1.9.

Table 2.

HR for incident chronic kidney disease by HOMA-IR with Cox proportion hazard models

Variable Unadjusted
Adjusted
Model 1a
Model 2b
Model 3c
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
HOMA-IR 1.22 (1.13–1.33) <0.001 1.19 (1.12–1.27) <0.001 1.16 (1.08–1.25) <0.001 1.13 (1.05–1.22) 0.001
Normal group 1 (Reference) - 1 (Reference) - 1 (Reference) - 1 (Reference) -
High group 1.49 (1.21–1.83) <0.001 1.66 (1.35–2.03) <0.001 1.44 (1.17–1.79) <0.001 1.40 (1.13–1.74) 0.002

CI, confidence interval; HOMA-IR, homeostasis model assessment-insulin resistance; HR, hazard ratio.

a

Adjusted for age and sex.

b

Model 1 + hypertension, body mass index, and total cholesterol.

c

Model 2 + alcohol drinking, smoking, and estimated glomerular filtration rate.

Table 3.

HR for incident chronic kidney disease by HOMA-IR, QUICKI, HOMA-AD, LAR, and HbA1C with Cox proportion hazard models

Variable Unadjusted
Adjusted
Model 1a
Model 2b
Model 3c
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
HOMA-IR 1.22 (1.13–1.33) <0.001 1.19 (1.12–1.27) <0.001 1.16 (1.08–1.25) <0.001 1.13 (1.05–1.22) 0.001
QUICKI*10 0.50 (0.33–0.74) <0.001 0.46 (0.31–0.67) <0.001 0.58 (0.39–0.86) 0.006 0.62 (0.41–0.92) 0.02
HOMA-AD 1.05 (1.00–1.11) 0.031 1.06 (1.01–1.11) 0.02 1.03 (0.97–1.08) 0.357 1.03 (0.98–1.08) 0.29
LAR 1.16 (1.04–1.29) 0.007 1.29 (1.14–1.47) <0.001 1.21 (1.05–1.40) 0.008 1.23 (1.06–1.42) 0.006

CI, confidence interval; HbA1C, hemoglobin A1c; HOMA-AD, homeostasis model assessment-adiponectin; HOMA-IR, homeostasis model assessment-insulin resistance; HR, hazard ratio; LAR, leptin-adiponectin ratio; QUICKI, quantitative insulin sensitivity check index;

a

Adjusted for age and sex.

b

Model 1 + hypertension, body mass index, and total cholesterol.

c

Model 2 + alcohol drinking, smoking, and estimated glomerular filtration rate.